(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 April 2022 (21.04.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/081976 A1

(51) International Patent Classification:
*A61K 31/553* (2006.01) *C07D 401/14* (2006.01)
*A61K 47/54* (2017.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2021/055186

(22) International Filing Date:
15 October 2021 (15.10.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/092,610 16 October 2020 (16.10.2020) US
63/153,599 25 February 2021 (25.02.2021) US

(71) Applicants: **DANA-FARBER CANCER INSTITUTE, INC.** [US/US]; 450 Brookline Avenue, Boston, Massachusetts 02215-5450 (US). **NEOMORPH, INC.** [US/US]; 5590 Morehouse Drive, San Diego, California 92121 (US).

(72) Inventors; and
(71) Applicants: **BEAR, Brian** [US/US]; c/o Neomorph, Inc., 5590 Morehouse Drive, San Diego, California 92121 (US). **PETRILLI, Whitney** [US/US]; c/o Neomorph, Inc., 5590 Morehouse Drive, San Diego, California 92121 (US).

(72) Inventors: **LIU, Hu**; 26 Blake Street, Newton, Massachusetts 02460 (US). **ZHANG, Tinghu**; 91 Chestnut Street, Brookline, Massachusetts 02445 (US). **JONES, Lyn**; 8 Russett Lane, Winchester, Massachusetts 01890 (US). **CHE, Jianwei**; 183 Morse Street, Sharon, Massachusetts 02067 (US).

(74) Agent: **CLARKE, J.D., PH.D., Daniel W.** et al.; Burns & Levinson LLP, 125 High Street, Boston, Massachusetts 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2022/081976 A1

(54) Title: PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE

(57) Abstract: Disclosed are compounds and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof that may cause degradation of various proteins e.g., IKZF2 (Helios). Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds to treat diseases and disorders associated with Helios and which may benefit from Helios degradation.